Table 1.
Characteristics of PRL and LH/FSH secreting tumor patients showing their sex, age, tumor type, MIB-1 index (%) along with BHB and PRL levels in the serum and whole blood (WB).
| Patient # | Sex | Age (years) | Tumor type (IHC) | MIB-1 (%) | BHB* (mM/L) | PRL (ng/mL) | Medical Therapy# | |
|---|---|---|---|---|---|---|---|---|
| Serum | WB | |||||||
| 1 | M | 45 | LH | 1–2 | 0.058 | 0.042 | 8.0 | No |
| 2 | F | 26 | LH | 2 | 0.106 | 0.054 | 37.0 | No |
| 3 | F | 77 | LHΨ | 1 | 0.438 | 0.255 | 30.0 | No |
| 4 | F | 64 | FSHΨ | 1 | 0.482 | 0.418 | 37.0 | No |
| 5 | M | 61 | FSH | 1 | 0.373 | 0.072 | Normal | No |
| 6 | M | 46 | FSH | 2–3 | 0.261 | 0.158 | 14.1 | No |
| 7 | F | 57 | FSH | 1 | 0.455 | 0.287 | NA | No |
| 8 | F | 77 | FSHΨ | 1–2 | 0.484 | 0.287 | 37.0 | No |
| 9 | F | 66 | LH/FSH | 2–3 | 0.331 | 0.225 | Normal | No |
| 10 | M | 81 | LH/FSH | 1 | 0.215 | 0.188 | NA | No |
| 11 | F | 25 | LH/FSH | 2 | 0.223 | 0.166 | 148.0 | No |
| 12 | F | 54 | LH/FSH | 1 | 0.135 | 0.086 | 51.2 | No |
| 13 | M | 53 | LH/FSH | 2 | 0.155 | 0.134 | 23.3 | No |
| 14 | M | 61 | LH/FSH | 1–2 | 0.304 | 0.252 | NA | No |
| 15 | M | 47 | LH/FSH | 1 | 0.268 | 0.103 | <1 | No |
| 16 | F | 65 | LH/FSH | 1 | 0.455 | 0.291 | NA | No |
| 17 | M | 59 | LH/FSH | 1–2 | 0.160 | 0.054 | 6.0 | No |
| 18 | M | 55 | LH/FSH | 2 | 0.104 | 0.037 | 23.0 | No |
| 19 | M | 79 | LH/FSH | 1 | 0.282 | 0.161 | 20.4 | No |
| 20 | M | 72 | LH/FSH | 1 | 0.091 | 0.038 | NA | No |
| 21 | F | 65 | LH/FSH | 1 | 0.560 | 0.334 | NA | No |
| 22 | M | 62 | LH/FSH | 1 | 0.210 | 0.092 | 17.4 | No |
| 23 | M | 71 | LH/FSH | 1–2 | 0.215 | 0.085 | 39.4 | No |
| 24 | M | 65 | LH/FSH | 2 | 0.238 | 0.105 | 13.5 | No |
| 25 | F | 49 | PRL | 3–4 | 0.930 | 0.937 | 79.4 | No |
| 26 | F | 34 | PRL | 2 | 0.656 | 0.482 | 274 | Yes |
| 27 | F | 36 | PRL | 3 | 0.640 | 0.416 | 197.2 | No |
| 28 | F | 22 | PRL | NA | 0.232 | 0.122 | Elevated | Yes |
| 29 | F | 33 | PRL | No staining | 0.624 | 0.444 | 114 | Yes |
| 30 | F | 50 | PRL | 1 | 0.614 | 0.513 | NA | No |
| 31 | F | 37 | PRL | 1–2 | 0.549 | 0.380 | 82.5 | No |
| 32 | M | 22 | PRL | 5–7 | 0.179 | 0.133 | 115.3 | Yes |
| 33 | M | 59 | PRL | No staining | 0.429 | 0.175 | 249.0 | Yes |
| 34 | F | 45 | PRL | 2 | 0.268 | 0.104 | 41 | No |
| 35 | F | 33 | PRL | 1 | 0.291 | 0.209 | 82.2 | Yes |
| 36 | F | 27 | PRL | 1 | 0.294 | 0.120 | 64.0 | Yes |
| 37 | M | 24 | PRL | 5–7 | 0.463 | 0.216 | 1029.0 | Yes |
| 38 | F | 53 | PRL | 1 | 0.567 | 0.355 | 10.0 | No |
| 39 | F | 46 | NF | 1 | 0.169 | 0.159 | 9.0 | No |
| 40 | M | 37 | NF | 3 | 0.078 | 0.057 | 7.6 | No |
| 41 | F | 39 | NF | 1 | 0.058 | 0.0416 | NA | No |
| 42 | M | 42 | NF | 1 | 0.470 | 0.313 | 7.4 | No |
| 43 | M | 65 | NF | 2 | 0.188 | 0.153 | NA | No |
| 44 | F | 75 | NF | 1 | 0.669 | 0.459 | NA | No |
| 45 | F | 72 | NF | 2 | 0.439 | 0.213 | NA | No |
| 46 | F | 73 | NF | 1 | 0.318 | 0.164 | NA | No |
| 47 | M | 73 | NF | 1 | 0.849 | No sample | 8.0 | No |
(IHC, Immunohistochemistry; LH, luteinizing hormone; FSH, follicle stimulating hormone; PRL, prolactin; NA, not available; PRL-reference range = 2–23 ng/mL; *, BHB levels measured by 1H NMR spectroscopy; Ψ, IHC was positive for LH/FSH, also showed scattered immunoreactivity for PRL, and these patient also showed elevated levels of PRL and BHB similar to prolactinoma patients; #, patients were treated with Cabergoline, 2–4 mg/week).